ILM peeling beneficial, not harmful

Article

Peeling the internal limiting membrane (ILM) may reduce the rate of premacular fibrosis (PMF) formation, according to a study published in the June 2008 issue of Retina.

Peeling the internal limiting membrane (ILM) may reduce the rate of premacular fibrosis (PMF) formation, according to a study published in the June 2008 issue of Retina.

Ramin Schadlu, MD of the Department of Ophthalmology and Visual Science at Washington University of St Louis, US and colleagues conducted a retrospective chart review to establish the rate of favourable outcomes after surgical ILM peeling to remove PMF. Patients undergoing pars plana vitrectomy (PPV) and ILM peeling (n=38) had visual acuity assessed before and three months after surgery. Complications and PMF recurrence were noted.

Patients with higher presurgical visual acuity had the most favourable outcomes, with no adverse events and high postsurgical visual acuity. Following surgery, visual acuity remained the same or improved in 89.5% of treated eyes. Visual acuity improvement averaged 2.2 lines. PMF recurred in 2.6% of treated eyes (n=1). Cataract formation was the most common adverse event; following extraction, two patients developed cystoid macular oedema (CME).

The researchers concluded that the rate of adverse events associated with ILM peeling was not as high as previously believed and that, within this group of patients, outcomes were not unfavourable.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.